Dataset Information

Multi-modality deep learning model reaches high prediction accuracy in the diagnosis of ovarian cancer.

ABSTRACT: We evaluated the diagnostic performance of a multimodal deep-learning (DL) model for ovarian mass differential diagnosis. This single-center retrospective study included 1,054 ultrasound (US)-detected ovarian tumors (699 benign and 355 malignant). Patients were randomly divided into training (n = 675), validation (n = 169), and testing (n = 210) sets. The model was developed using ResNet-50. Three DL-based models were proposed for benign-malignant classification of these lesions: single-modality model that only utilized US images; dual-modality model that used US images and menopausal status as inputs; and multi-modality model that integrated US images, menopausal status, and serum indicators. After 5-fold cross-validation, 210 lesions were tested. We evaluated the three models using the area under the curve (AUC), accuracy, sensitivity, and specificity. The multimodal model outperformed the single- and dual-modality models with 93.80% accuracy and 0.983 AUC. The Multimodal ResNet-50 DL model outperformed the single- and dual-modality models in identifying benign and malignant ovarian tumors.

SUBMITTER: Wang Z

PROVIDER: S-EPMC10959660 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Multi-modality deep learning model reaches high prediction accuracy in the diagnosis of ovarian cancer.

Wang Zimo Z Luo Shuyu S Chen Jing J Jiao Yang Y Cui Chen C Shi Siyuan S Yang Yang Y Zhao Junyi J Jiang Yitao Y Zhang Yujuan Y Xu Fanhua F Xu Jinfeng J Lin Qi Q Dong Fajin F

iScience 20240304 4

We evaluated the diagnostic performance of a multimodal deep-learning (DL) model for ovarian mass differential diagnosis. This single-center retrospective study included 1,054 ultrasound (US)-detected ovarian tumors (699 benign and 355 malignant). Patients were randomly divided into training (n = 675), validation (n = 169), and testing (n = 210) sets. The model was developed using ResNet-50. Three DL-based models were proposed for benign-malignant classification of these lesions: single-modality ...[more]

PMID: 38523785

Similar Datasets

Project description:Background: Breast ultrasound is the first choice for breast tumor diagnosis in China, but the Breast Imaging Reporting and Data System (BI-RADS) categorization routinely used in the clinic often leads to unnecessary biopsy. Radiologists have no ability to predict molecular subtypes with important pathological information that can guide clinical treatment. Materials and Methods: This retrospective study collected breast ultrasound images from two hospitals and formed training, test and external test sets after strict selection, which included 2,822, 707, and 210 ultrasound images, respectively. An optimized deep learning model (DLM) was constructed with the training set, and the performance was verified in both the test set and the external test set. Diagnostic results were compared with the BI-RADS categorization determined by radiologists. We divided breast cancer into different molecular subtypes according to hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expression. The ability to predict molecular subtypes using the DLM was confirmed in the test set. Results: In the test set, with pathological results as the gold standard, the accuracy, sensitivity and specificity were 85.6, 98.7, and 63.1%, respectively, according to the BI-RADS categorization. The same set achieved an accuracy, sensitivity, and specificity of 89.7, 91.3, and 86.9%, respectively, when using the DLM. For the test set, the area under the curve (AUC) was 0.96. For the external test set, the AUC was 0.90. The diagnostic accuracy was 92.86% with the DLM in BI-RADS 4a patients. Approximately 70.76% of the cases were judged as benign tumors. Unnecessary biopsy was theoretically reduced by 67.86%. However, the false negative rate was 10.4%. A good prediction effect was shown for the molecular subtypes of breast cancer with the DLM. The AUC were 0.864, 0.811, and 0.837 for the triple-negative subtype, HER2 (+) subtype and HR (+) subtype predictions, respectively. Conclusion: This study showed that the DLM was highly accurate in recognizing breast tumors from ultrasound images. Thus, the DLM can greatly reduce the incidence of unnecessary biopsy, especially for patients with BI-RADS 4a. In addition, the predictive ability of this model for molecular subtypes was satisfactory,which has specific clinical application value.

Project description:Deep learning has shown significant value in automating radiological diagnostics but can be limited by a lack of generalizability to external datasets. Leveraging the geometric principles of non-Euclidean space, certain geometric deep learning approaches may offer an alternative means of improving model generalizability. This study investigates the potential advantages of hyperbolic convolutional neural networks (HCNNs) over traditional convolutional neural networks (CNNs) in neuroimaging tasks. We conducted a comparative analysis of HCNNs and CNNs across various medical imaging modalities and diseases, with a focus on a compiled multi-modality neuroimaging dataset. The models were assessed for their performance parity, robustness to adversarial attacks, semantic organization of embedding spaces, and generalizability. Zero-shot evaluations were also performed with ischemic stroke non-contrast CT images. HCNNs matched CNNs' performance in less complex settings and demonstrated superior semantic organization and robustness to adversarial attacks. While HCNNs equaled CNNs in out-of-sample datasets identifying Alzheimer's disease, in zero-shot evaluations, HCNNs outperformed CNNs and radiologists. HCNNs deliver enhanced robustness and organization in neuroimaging data. This likely underlies why, while HCNNs perform similarly to CNNs with respect to in-sample tasks, they confer improved generalizability. Nevertheless, HCNNs encounter efficiency and performance challenges with larger, complex datasets. These limitations underline the need for further optimization of HCNN architectures. HCNNs present promising improvements in generalizability and resilience for medical imaging applications, particularly in neuroimaging. Despite facing challenges with larger datasets, HCNNs enhance performance under adversarial conditions and offer better semantic organization, suggesting valuable potential in generalizable deep learning models in medical imaging and neuroimaging diagnostics.

Project description:While synergistic drug combinations are more effective at fighting tumors with complex pathophysiology, preference compensating mechanisms, and drug resistance, the identification of novel synergistic drug combinations, especially complex higher-order combinations, remains challenging due to the size of combination space. Even though certain computational methods have been used to identify synergistic drug combinations in lieu of traditional in vitro and in vivo screening tests, the majority of previously published work has focused on predicting synergistic drug pairs for specific types of cancer and paid little attention to the sophisticated high-order combinations. The main objective of this study is to develop a deep learning-based approach that integrated multi-omics data to predict novel synergistic multi-drug combinations (DeepMDS) in a given cell line. To develop this approach, we firstly created a dataset comprising of gene expression profiles of cancer cell lines, target information of anti-cancer drugs, and drug response against a large variety of cancer cell lines. Based on the principle of a fully connected feed forward Deep Neural Network, the proposed model was constructed using this dataset, which achieved a high performance with a Mean Square Error (MSE) of 2.50 and a Root Mean Squared Error (RMSE) of 1.58 in the regression task, and gave the best classification accuracy of 0.94, an area under the Receiver Operating Characteristic curve (AUC) of 0.97, a sensitivity of 0.95, and a specificity of 0.93. Furthermore, we utilized three breast cancer cell subtypes (MCF-7, MDA-MD-468 and MDA-MB-231) and one lung cancer cell line A549 to validate the predicted results of our model, showing that the predicted top-ranked multi-drug combinations had superior anti-cancer effects to other combinations, particularly those that were widely used in clinical treatment. Our model has the potential to increase the practicality of expanding the drug combinational space and to leverage its capacity to prioritize the most effective multi-drug combinational therapy for precision oncology applications.

Dataset Information

Multi-modality deep learning model reaches high prediction accuracy in the diagnosis of ovarian cancer.

Publications

Multi-modality deep learning model reaches high prediction accuracy in the diagnosis of ovarian cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets